Zusammenfassung
In der Definition der psoriatischen Erkrankung wurde früher und wird heute umso mehr auf die notwendige genetische Prädisposition des Erkrankten sowie auf die Abhängigkeit des Erkrankungsverlaufes von Umweltfaktoren hingewiesen. Die Psoriasis ist eine irritable Dermatose, d. h. sie kann durch unterschiedliche endogene und exogene Triggermechanismen sowohl zur Exazerbation als auch zur Manifestation gebracht werden. Das Wissen um Provokationsfaktoren ist wichtig für den klinischen Alltag. Diese Übersicht konzentriert sich auf die wichtigsten Triggerfaktoren (Infekte/Superantigene, Verletzungen/Köbner-Phänomen, Stress/Neuropeptide, Rauchen, Alkohol, Medikamente) und informiert über die derzeit vorliegenden Daten zur Einordnung dieser Triggerfaktoren in ein ätiopathologisches Konzept.
Abstract
Psoriasis is often defined as a disease in which there is a genetic predisposition but environmental stimuli ("trigger factors") are also necessary for clinical expression. Various endogenous and exogenous factors can either induce or exacerbate the clinical features. Knowledge of these factors is of primary importance in clinical practice. This review focuses on the most common environmental trigger factors (infection/superantigens, injury/Köbner phenomenon, stress/neuropeptides, smoking and alcohol) and evaluates the clinical and experimental concepts to explain "environmentally" triggered psoriasis.
Literatur
Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE (2001) A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. Br J Dermatol 145:886–890
Ortonne JP (1996) Aetiology and pathogenesis of psoriasis. Br J Dermatol 135:1–5
Gilhar A, Ullmann Y, Kerner H et al. (2002) Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes of psoriasis by cells with natural killer receptors: J Invest Dermatol 119:384–391
Boehncke WH, Hardt-Weinelt K, Nilsson H et al. (2001) Antagonistic effects of the staphylococcal enterotoxin a mutant, sea (F47A/D227A), on psoriasis in the SCID-hu xenogeneic transplantation model. J Invest Dermatol 116:596–601
Baker BS, Powles A, Garioch JJ et al. (1997) Differential T-cell reactivity to the round and oval forms of Pitysporum in the skin of patients with psoriasis. Br J Dermatol 136:319–325
Mallon E (2000) Retroviruses and psoriasis. Curr Opin Infect Dis 13:103–107
Weiss G, Shemer A, Trau H (2002) The Koebner phenomenon: review of the literature. J Eur Acad Dermatol Venereol 16:241–248
Kahofer P, Aberer E (2002) Psoriasis as Koebner phenomenon in erythema migrans. Hautarzt 53:805–807
Raychaudhuri SP, Gross J (2000) Psoriasis risk factors: role of lifestyle practices. Cutis 66:348–352
Seville RH (1989) Stress and psoriasis: the importance of insight and empathy in prognosis. J Am Acad Dermatol 20:97–100
Scholzen T, Armstrong CA, Bunnett NW et al. (1998) Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 7:81–96
Luger TA (2002) Neuromediators-a crucial component of the skin immune system. J Dermatol Sci 30:87–93
Schmid-Ott G, Malewski P, Kunsebeck HW et al. (2000) Illness-related stress in psoriasis vulgaris. Validation of the daily stress inventory. Hautarzt 51:496–501
Gupta MA, Gupta AK, Watteel GN (1996) Cigarette smoking in men may be a risk factor for increased severity of psoriasis of the extremities. Br J Dermatol 135:859–860
Naldi L, Peli L, Parazzini F (1999) Association of early-stage psoriasis with smoking and male consumption: evidence from an Italian case-control study. Arch Dermatol 135:1479–1484
Hagforsen E, Edvinsson M, Nordlind K, Michaelsson G (2002) Expression of nicotinic receptors in the skin of patients with palmoplantar pustulosis. Br J Dermatol 146:383–391
Ockenfels HM, Keim-Maas C, Funk R et al. (1996) Ethanol enhances the IFN-γ, TGF-α and IL-6 secretion in psoriatic co-cultures. Br J Dermatol 135:746–751
Gupta MA, Schork NJ, Gupta AK, Ellis CN (1993) Alcohol intake and treatment responsiveness of psoriasis: a prospective study. J Am Acad Dermatol 28:730–732
Razani-Boroujerdi S, Savage SM, Sopori ML (1994) Alcohol-induced changes in the immune response: immunological effects of chronic ethanol intake are genetically regulated. Toxicol Appl Pharmacol 127:37–43
Ockenfels HM, Wagner SN, Keim-Maas C et al. (1996) Lithium and psoriasis: cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium. Arch Dermatol Res 288:173–178
Ockenfels HM, Nussbaum G, Schneck B et al. (1996) The effect of Cyclosporin A and FK 506 on the cAMP content in psoriatic keratinocytes. Skin Pharmacol 9:281–288
Beyaert R, Schulze-Osthoff K, Roy F van, Fiers W (1992) Synergistic induction of interleukin-6 by tumor necrosis factor and lithium chloride in mice: possible role in the triggering and exacerbation of psoriasis by lithium treatment. Eur J Immunol 22:2181–2184
Schopf RE, Ockenfels HM, Schultewolter T, Morsches B (1993) Chloroquine stimulates the mitogen-driven lymphocyte proliferation in patients with psoriasis. Dermatol 187:100–103
Demidem A, Taylor JR, Grammer SF, Streilein JW (1992) Effects of chloroquine on antigen-presenting functions of epidermal cells from normal and psoriatic skin. J Invest Dermatol 98:181–186
Wellems TE (1992) How chloroquine works. Nature 355:108–109
Tsankov N, Angelova I, Kazandjieva J (2000) Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 1:159–165
Marsland AM, Griffiths CE (2001) Treatments for chronic palmoplantar pustular psoriasis. Skin Therapy Lett 6:3–5
Wolfer LU, Goerdt S, Schroder K et al. (1996) Interferon-alpha-induced psoriasis vulgaris. Hautarzt 47:124–128
Gilleaudeau P, Vallat VP, Carter DM, Gottlieb AB (1993) Angiotensin-converting enzyme inhibitors as possible exacerbation drugs in psoriasis. J Am Acad Dermatol 28:490–492
Wolf R, Ruocco V (1999) Triggered psoriasis. Adv Exp Med Biol 455:221–225
Steckelings UM, Artuc M, Paul M (1996) Angiotensin II stimulates proliferation of primary human keratinocytes via a non-AT1, non-AT2 angiotensin receptor. Biochem Biophys Res Commun 229:329–333
Marquart-Elbaz C, Grosshans E, Lipsker D, Lipsker D (2002) Sartans, angiotensin II receptor antagonists, can induce psoriasis. Br J Dermatol 147:617–618
Author information
Authors and Affiliations
Corresponding author
Additional information
Diese Übersichtsarbeit ist Herrn Professor Dr. med. Manfred Goos mit besten Wünschen zum 65. Geburtstag gewidmet.
Rights and permissions
About this article
Cite this article
Ockenfels, H.M. Triggermechanismen der Psoriasis. Hautarzt 54, 215–223 (2003). https://doi.org/10.1007/s00105-003-0494-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-003-0494-5